StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Acadia Pharmaceuticals (ACAD) PT Lowered to $22 at BofA Securities
May 10, 2024 5:24 AM
BofA Securities analyst Tazeen Ahmad lowered the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $22.00 (from $26.00) while maintaining ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst PT Change
Next Articles
Acadia Pharmaceuticals (ACAD) PT Lowered to $17 at Oppenheimer
May 10, 2024 4:57 AM
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
May 9, 2024 4:58 PM
Acadia Pharmaceuticals (ACAD) PT Lowered to $28 at Baird
May 9, 2024 6:21 AM
Form 10-Q ACADIA PHARMACEUTICALS For: Mar 31
May 9, 2024 6:03 AM
Acadia Pharmaceuticals (ACAD) PT Lowered to $21 at Mizuho
May 9, 2024 5:52 AM
Form 8-K ACADIA PHARMACEUTICALS For: May 08
May 8, 2024 4:12 PM
Acadia Pharma (ACAD) Tops Q1 EPS by 5c, Misses on Revenue; Offers FY24 Guidance
May 8, 2024 4:09 PM
Acadia Pharmaceuticals Reports First Quarter 2024 Financial Results and Operating Overview
May 8, 2024 4:05 PM
